NASDAQ:ACRV Acrivon Therapeutics Q4 2025 Earnings Results & Report $1.76 +0.04 (+2.33%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$1.80 +0.04 (+2.10%) As of 10/15/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Acrivon Therapeutics met analyst earnings expectations in its Q4 2025 results, released March 19, 2026. The company reported EPS of -$0.49 versus the -$0.49 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 19, 2026TimeBefore Market OpensConference Call7:00 AM ET Acrivon Therapeutics EPS ResultsActual EPS-$0.49Consensus EPS -$0.49Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersAcrivon Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.17 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAcrivon Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Acrivon Therapeutics Q4 2025 Earnings FAQ Did Acrivon Therapeutics beat earnings estimates for Q4 2025? Acrivon Therapeutics (NASDAQ:ACRV) reported earnings of -$0.49 per share for Q4 2025, matching the consensus estimate of -$0.49. The report was announced on Thursday, March 19, 2026. When is Acrivon Therapeutics' next earnings date? Acrivon Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Acrivon Therapeutics on the company's earnings history page. Acrivon Therapeutics Earnings HeadlinesAcrivon Therapeutics (NASDAQ:ACRV) Upgraded to "Hold" at Wall Street ZenOctober 5, 2026 | americanbankingnews.comAcrivon Therapeutics to Present at the 2026 Cantor Global Healthcare ConferenceSeptember 2, 2026 | globenewswire.comThis Tiny Sub-$1 Gold-Silver Royalty Stock Is Ready to RunA gold-silver royalty firm just closed the largest transaction in its history a new gold streaming deal on a producing mine. The company earns cash flow without operating a single mine, and shares still trade below $1. A major mining financier has already invested and joins the CEO in an exclusive interview. | Digest Publishing (Ad)Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business OfficerAugust 31, 2026 | globenewswire.comAcrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data CatalystsAugust 13, 2026 | finance.yahoo.comAcrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 StudyAugust 5, 2026 | globenewswire.comSee More Acrivon Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Acrivon Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acrivon Therapeutics and other key companies, straight to your email. Email Address About Acrivon TherapeuticsAcrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with difficult-to-treat cancers. The company uses its Acrivon Predictive Precision Oncology (AP3) platform to identify tumor characteristics that may predict a patient’s response to specific targeted therapies. Acrivon’s lead program is ACR-368, an orally administered small-molecule inhibitor designed to target the checkpoint kinase 1 (CHK1) and WEE1 proteins, which help regulate tumor-cell replication and DNA damage responses. The company is evaluating ACR-368 in selected solid tumors, including ovarian and endometrial cancers, using its OncoSignature approach as a potential biomarker-based companion diagnostic to identify patients most likely to benefit. The company is also advancing additional targeted oncology programs, including ACR-2316, a selective WEE1 inhibitor. Acrivon was founded in 2018 and is headquartered in Watertown, Massachusetts. Its research and clinical development activities are focused on advancing precision treatments for cancer patients in the United States and other major clinical markets.View Acrivon Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
